 | • レポートコード：MRC2-11QY12151 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は血液悪性腫瘍のグローバル市場について調査・分析したレポートです。種類別（白血病、リンパ腫、骨髄腫）市場規模、用途別（病院薬局、医療店、Eコマースプラットフォーム）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別血液悪性腫瘍の競争状況、市場シェア ・世界の血液悪性腫瘍市場：種類別市場規模 2015年-2020年（白血病、リンパ腫、骨髄腫） ・世界の血液悪性腫瘍市場：種類別市場規模予測 2021年-2026年（白血病、リンパ腫、骨髄腫） ・世界の血液悪性腫瘍市場：用途別市場規模 2015年-2020年（病院薬局、医療店、Eコマースプラットフォーム） ・世界の血液悪性腫瘍市場：用途別市場規模予測 2021年-2026年（病院薬局、医療店、Eコマースプラットフォーム） ・北米の血液悪性腫瘍市場分析：米国、カナダ ・ヨーロッパの血液悪性腫瘍市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの血液悪性腫瘍市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の血液悪性腫瘍市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの血液悪性腫瘍市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AbbVie、Bristol-Myers Squibb、Celgene、Roche、GlaxoSmithKline、Johnson & Johnson、Novartis、Pfizer、Teva Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Hematologic malignancies are forms of cancer that begin in the cells of blood-forming tissue, such as the bone marrow, or in the cells of the immune system.
Market Analysis and Insights: Global Hematological Malignancies Market
The global Hematological Malignancies market size is projected to reach US$ 30650 million by 2026, from US$ 29310 million in 2020, at a CAGR of 4.3%% during 2021-2026.
Global Hematological Malignancies Scope and Market Size
Hematological Malignancies market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Hematological Malignancies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
AbbVie
Bristol-Myers Squibb
Celgene
Roche
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Teva Pharmaceutical
Market segment by Type, the product can be split into
Leukemia
Lymphoma
Myeloma
Market segment by Application, split into
Hospital Pharmacies
Medical Stores
E-commerce Platform
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hematological Malignancies Revenue
1.4 Market by Type
1.4.1 Global Hematological Malignancies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Leukemia
1.4.3 Lymphoma
1.4.4 Myeloma
1.5 Market by Application
1.5.1 Global Hematological Malignancies Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Medical Stores
1.5.4 E-commerce Platform
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Hematological Malignancies Market Perspective (2015-2026)
2.2 Global Hematological Malignancies Growth Trends by Regions
2.2.1 Hematological Malignancies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Hematological Malignancies Historic Market Share by Regions (2015-2020)
2.2.3 Hematological Malignancies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Hematological Malignancies Market Growth Strategy
2.3.6 Primary Interviews with Key Hematological Malignancies Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Hematological Malignancies Players by Market Size
3.1.1 Global Top Hematological Malignancies Players by Revenue (2015-2020)
3.1.2 Global Hematological Malignancies Revenue Market Share by Players (2015-2020)
3.1.3 Global Hematological Malignancies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hematological Malignancies Market Concentration Ratio
3.2.1 Global Hematological Malignancies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Hematological Malignancies Revenue in 2019
3.3 Hematological Malignancies Key Players Head office and Area Served
3.4 Key Players Hematological Malignancies Product Solution and Service
3.5 Date of Enter into Hematological Malignancies Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Hematological Malignancies Historic Market Size by Type (2015-2020)
4.2 Global Hematological Malignancies Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Hematological Malignancies Market Size by Application (2015-2020)
5.2 Global Hematological Malignancies Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Hematological Malignancies Market Size (2015-2020)
6.2 Hematological Malignancies Key Players in North America (2019-2020)
6.3 North America Hematological Malignancies Market Size by Type (2015-2020)
6.4 North America Hematological Malignancies Market Size by Application (2015-2020)
7 Europe
7.1 Europe Hematological Malignancies Market Size (2015-2020)
7.2 Hematological Malignancies Key Players in Europe (2019-2020)
7.3 Europe Hematological Malignancies Market Size by Type (2015-2020)
7.4 Europe Hematological Malignancies Market Size by Application (2015-2020)
8 China
8.1 China Hematological Malignancies Market Size (2015-2020)
8.2 Hematological Malignancies Key Players in China (2019-2020)
8.3 China Hematological Malignancies Market Size by Type (2015-2020)
8.4 China Hematological Malignancies Market Size by Application (2015-2020)
9 Japan
9.1 Japan Hematological Malignancies Market Size (2015-2020)
9.2 Hematological Malignancies Key Players in Japan (2019-2020)
9.3 Japan Hematological Malignancies Market Size by Type (2015-2020)
9.4 Japan Hematological Malignancies Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Hematological Malignancies Market Size (2015-2020)
10.2 Hematological Malignancies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hematological Malignancies Market Size by Type (2015-2020)
10.4 Southeast Asia Hematological Malignancies Market Size by Application (2015-2020)
11 India
11.1 India Hematological Malignancies Market Size (2015-2020)
11.2 Hematological Malignancies Key Players in India (2019-2020)
11.3 India Hematological Malignancies Market Size by Type (2015-2020)
11.4 India Hematological Malignancies Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Hematological Malignancies Market Size (2015-2020)
12.2 Hematological Malignancies Key Players in Central & South America (2019-2020)
12.3 Central & South America Hematological Malignancies Market Size by Type (2015-2020)
12.4 Central & South America Hematological Malignancies Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 AbbVie
13.1.1 AbbVie Company Details
13.1.2 AbbVie Business Overview
13.1.3 AbbVie Hematological Malignancies Introduction
13.1.4 AbbVie Revenue in Hematological Malignancies Business (2015-2020))
13.1.5 AbbVie Recent Development
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Details
13.2.2 Bristol-Myers Squibb Business Overview
13.2.3 Bristol-Myers Squibb Hematological Malignancies Introduction
13.2.4 Bristol-Myers Squibb Revenue in Hematological Malignancies Business (2015-2020)
13.2.5 Bristol-Myers Squibb Recent Development
13.3 Celgene
13.3.1 Celgene Company Details
13.3.2 Celgene Business Overview
13.3.3 Celgene Hematological Malignancies Introduction
13.3.4 Celgene Revenue in Hematological Malignancies Business (2015-2020)
13.3.5 Celgene Recent Development
13.4 Roche
13.4.1 Roche Company Details
13.4.2 Roche Business Overview
13.4.3 Roche Hematological Malignancies Introduction
13.4.4 Roche Revenue in Hematological Malignancies Business (2015-2020)
13.4.5 Roche Recent Development
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Details
13.5.2 GlaxoSmithKline Business Overview
13.5.3 GlaxoSmithKline Hematological Malignancies Introduction
13.5.4 GlaxoSmithKline Revenue in Hematological Malignancies Business (2015-2020)
13.5.5 GlaxoSmithKline Recent Development
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Details
13.6.2 Johnson & Johnson Business Overview
13.6.3 Johnson & Johnson Hematological Malignancies Introduction
13.6.4 Johnson & Johnson Revenue in Hematological Malignancies Business (2015-2020)
13.6.5 Johnson & Johnson Recent Development
13.7 Novartis
13.7.1 Novartis Company Details
13.7.2 Novartis Business Overview
13.7.3 Novartis Hematological Malignancies Introduction
13.7.4 Novartis Revenue in Hematological Malignancies Business (2015-2020)
13.7.5 Novartis Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview
13.8.3 Pfizer Hematological Malignancies Introduction
13.8.4 Pfizer Revenue in Hematological Malignancies Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Teva Pharmaceutical
13.9.1 Teva Pharmaceutical Company Details
13.9.2 Teva Pharmaceutical Business Overview
13.9.3 Teva Pharmaceutical Hematological Malignancies Introduction
13.9.4 Teva Pharmaceutical Revenue in Hematological Malignancies Business (2015-2020)
13.9.5 Teva Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Hematological Malignancies Key Market Segments
Table 2. Key Players Covered: Ranking by Hematological Malignancies Revenue
Table 3. Ranking of Global Top Hematological Malignancies Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hematological Malignancies Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Leukemia
Table 6. Key Players of Lymphoma
Table 7. Key Players of Myeloma
Table 8. Global Hematological Malignancies Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Hematological Malignancies Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Hematological Malignancies Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Hematological Malignancies Market Share by Regions (2015-2020)
Table 12. Global Hematological Malignancies Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Hematological Malignancies Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Hematological Malignancies Market Growth Strategy
Table 18. Main Points Interviewed from Key Hematological Malignancies Players
Table 19. Global Hematological Malignancies Revenue by Players (2015-2020) (Million US$)
Table 20. Global Hematological Malignancies Market Share by Players (2015-2020)
Table 21. Global Top Hematological Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies as of 2019)
Table 22. Global Hematological Malignancies by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hematological Malignancies Product Solution and Service
Table 25. Date of Enter into Hematological Malignancies Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 28. Global Hematological Malignancies Market Size Share by Type (2015-2020)
Table 29. Global Hematological Malignancies Revenue Market Share by Type (2021-2026)
Table 30. Global Hematological Malignancies Market Size Share by Application (2015-2020)
Table 31. Global Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 32. Global Hematological Malignancies Market Size Share by Application (2021-2026)
Table 33. North America Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Hematological Malignancies Market Share (2019-2020)
Table 35. North America Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 36. North America Hematological Malignancies Market Share by Type (2015-2020)
Table 37. North America Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 38. North America Hematological Malignancies Market Share by Application (2015-2020)
Table 39. Europe Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Hematological Malignancies Market Share (2019-2020)
Table 41. Europe Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Hematological Malignancies Market Share by Type (2015-2020)
Table 43. Europe Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Hematological Malignancies Market Share by Application (2015-2020)
Table 45. China Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 46. China Key Players Hematological Malignancies Market Share (2019-2020)
Table 47. China Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 48. China Hematological Malignancies Market Share by Type (2015-2020)
Table 49. China Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 50. China Hematological Malignancies Market Share by Application (2015-2020)
Table 51. Japan Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Hematological Malignancies Market Share (2019-2020)
Table 53. Japan Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Hematological Malignancies Market Share by Type (2015-2020)
Table 55. Japan Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Hematological Malignancies Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Hematological Malignancies Market Share (2019-2020)
Table 59. Southeast Asia Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Hematological Malignancies Market Share by Type (2015-2020)
Table 61. Southeast Asia Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Hematological Malignancies Market Share by Application (2015-2020)
Table 63. India Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 64. India Key Players Hematological Malignancies Market Share (2019-2020)
Table 65. India Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 66. India Hematological Malignancies Market Share by Type (2015-2020)
Table 67. India Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 68. India Hematological Malignancies Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Hematological Malignancies Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Hematological Malignancies Market Share (2019-2020)
Table 71. Central & South America Hematological Malignancies Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Hematological Malignancies Market Share by Type (2015-2020)
Table 73. Central & South America Hematological Malignancies Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Hematological Malignancies Market Share by Application (2015-2020)
Table 75. AbbVie Company Details
Table 76. AbbVie Business Overview
Table 77. AbbVie Product
Table 78. AbbVie Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 79. AbbVie Recent Development
Table 80. Bristol-Myers Squibb Company Details
Table 81. Bristol-Myers Squibb Business Overview
Table 82. Bristol-Myers Squibb Product
Table 83. Bristol-Myers Squibb Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 84. Bristol-Myers Squibb Recent Development
Table 85. Celgene Company Details
Table 86. Celgene Business Overview
Table 87. Celgene Product
Table 88. Celgene Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 89. Celgene Recent Development
Table 90. Roche Company Details
Table 91. Roche Business Overview
Table 92. Roche Product
Table 93. Roche Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 94. Roche Recent Development
Table 95. GlaxoSmithKline Company Details
Table 96. GlaxoSmithKline Business Overview
Table 97. GlaxoSmithKline Product
Table 98. GlaxoSmithKline Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 99. GlaxoSmithKline Recent Development
Table 100. Johnson & Johnson Company Details
Table 101. Johnson & Johnson Business Overview
Table 102. Johnson & Johnson Product
Table 103. Johnson & Johnson Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 104. Johnson & Johnson Recent Development
Table 105. Novartis Company Details
Table 106. Novartis Business Overview
Table 107. Novartis Product
Table 108. Novartis Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 109. Novartis Recent Development
Table 110. Pfizer Business Overview
Table 111. Pfizer Product
Table 112. Pfizer Company Details
Table 113. Pfizer Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 114. Pfizer Recent Development
Table 115. Teva Pharmaceutical Company Details
Table 116. Teva Pharmaceutical Business Overview
Table 117. Teva Pharmaceutical Product
Table 118. Teva Pharmaceutical Revenue in Hematological Malignancies Business (2015-2020) (Million US$)
Table 119. Teva Pharmaceutical Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Hematological Malignancies Market Share by Type: 2020 VS 2026
Figure 2. Leukemia Features
Figure 3. Lymphoma Features
Figure 4. Myeloma Features
Figure 5. Global Hematological Malignancies Market Share by Application: 2020 VS 2026
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Medical Stores Case Studies
Figure 8. E-commerce Platform Case Studies
Figure 9. Hematological Malignancies Report Years Considered
Figure 10. Global Hematological Malignancies Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Hematological Malignancies Market Share by Regions: 2020 VS 2026
Figure 12. Global Hematological Malignancies Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Hematological Malignancies Market Share by Players in 2019
Figure 15. Global Top Hematological Malignancies Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hematological Malignancies as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Hematological Malignancies Revenue in 2019
Figure 17. North America Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Hematological Malignancies Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
血液悪性腫瘍性疾患の世界市場（～2026年） Market Analysis and Insights: Global Hematological Malignancies Disease Market The global Hematological Malignancies Disease market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Hematological Malignancies Disease Scope and …- 非血液がんの世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 非血液がん治療の世界市場（～2026年） Non-Hematological cancers which cover lung cancer, prostate cancer, breast cancer and others, this type of cancer are not show easily diagnosis and the treatment process is also show long that some time it lead to the death of the patient. North America has the huge number of population suffering fr…
- 血液疾患診断・治療の世界市場（～2026年） Hematology, a branch of medicine, deals with the prevention, diagnosis, and treatment of blood diseases. It includes problems associated with red blood cells (RBCs), white blood cells (WBCs), platelets, bone marrow, blood vessels, spleen, lymph nodes, and proteins involved in bleeding and clotting p…
- 成人T細胞白血病/リンパ腫治療の世界市場（～2026年） Adult T-cell lymphoma/leukemia (ATL) is a rare T-cell lymphoproliferative neoplasm caused by human T-lymphotrophic virus 1. In its more common, aggressive forms, ATL carries one of the poorest prognoses of the non-Hodgkin lymphomas. The disease has clinical subtypes (ie, acute, lymphoma, chronic, an…